4.5 Article

The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study

Journal

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
Volume 52, Issue 1, Pages 43-53

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jpainsymman.2015.12.314

Keywords

Chronic pain; itch; pruritus; systemic sclerosis; scleroderma; health-related quality of life

Funding

  1. Canadian Institutes of Health Research [FRN 83518]
  2. Scleroderma Society of Canada
  3. Scleroderma Society of Ontario
  4. Sclerodermie Quebec
  5. Cure Scleroderma Foundation
  6. INOVA Diagnostics Inc. (San Diego, CA)
  7. Dr. Fooke Laboratorien GmbH (Neuss, Germany)
  8. Euroimmun (Lubeck, Germany)
  9. Mikrogen GmbH (Neuried, Germany)
  10. Fonds de la Recherche en Sante du Quebec
  11. Canadian Arthritis Network
  12. Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC
  13. Pfizer
  14. Actelion Pharmaceuticals
  15. bequest from the estate of Mrs. Beryl Ivey

Ask authors/readers for more resources

Context. Pain and itch are common symptoms reported by patients with systemic sclerosis (SSc; scleroderma), which can markedly diminish function and health-related quality of life (HRQL). Objectives. The aim of this exploratory study was to examine the impact that pain, itch, and the interaction of both have on function (depressive symptoms, overall disability, fatigue, sleep disturbance) and HRQL in patients with SSc. Methods. A total of 964 patients from the Canadian Scleroderma Reserch Group Registry completed questionnaires measuring itch and pain severity, function, and HRQL. Multiple regression analyses were performed to examine the impact that pain, itch, and pain x itch interaction have on each outcome variable while controlling for demographic measures. A P-value of <= 0.01 was required for a difference to be deemed statistically significant. Results. Our results revealed that patients with SSc who reported higher pain and itch severity were also more likely to have greater depressive symptoms, overall disability, sleep and fatigue problems, even when demographic measures were controlled for (P-values <= 0.001). Similar results were obtained for HRQL, regardless of the domains (P-values <= 0.001). A significant association between pain x itch interaction and sleep (P = 0.002), physical functioning (P = 0.003), and general health (P <= 0.001) variables also was found. Further investigation of the nature of the pain x itch interaction showed that the effect of pain severity on outcome variables diminishes as itch severity increases. Conclusion. Both pain and itch appear to have a detrimental impact on functioning and HRQL in patients with SSc, suggesting that more targeted approaches to symptom management are warranted. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available